CARsgen Therapeutics Holdings Future Growth
Future criteria checks 2/6
CARsgen Therapeutics Holdings is forecast to grow earnings and revenue by 24.6% and 114.3% per annum respectively. EPS is expected to grow by 25% per annum. Return on equity is forecast to be -97% in 3 years.
Key information
24.6%
Earnings growth rate
25.0%
EPS growth rate
| Biotechs earnings growth | 42.2% |
| Revenue growth rate | 114.3% |
| Future return on equity | -97.0% |
| Analyst coverage | Low |
| Last updated | 30 Oct 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2,162 | -328 | N/A | N/A | 2 |
| 12/31/2025 | 720 | -622 | N/A | N/A | 2 |
| 12/31/2024 | 112 | -694 | N/A | N/A | 2 |
| 6/30/2024 | 6 | -695 | -575 | -569 | N/A |
| 3/31/2024 | 3 | -721 | -520 | -512 | N/A |
| 12/31/2023 | N/A | -748 | -464 | -455 | N/A |
| 9/30/2023 | N/A | -834 | -480 | -465 | N/A |
| 6/30/2023 | N/A | -920 | -495 | -474 | N/A |
| 3/31/2023 | N/A | -906 | -638 | -559 | N/A |
| 12/31/2022 | N/A | -892 | -782 | -643 | N/A |
| 9/30/2022 | 13 | -810 | -846 | -640 | N/A |
| 6/30/2022 | 26 | -727 | -910 | -637 | N/A |
| 3/31/2022 | 26 | -2,736 | -800 | -575 | N/A |
| 12/31/2021 | 26 | -4,744 | -691 | -512 | N/A |
| 9/30/2021 | 13 | -4,831 | -540 | -431 | N/A |
| 6/30/2021 | N/A | -4,917 | -390 | -350 | N/A |
| 3/31/2021 | N/A | -2,991 | -352 | -323 | N/A |
| 12/31/2020 | N/A | -1,064 | -314 | -295 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2171 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2171 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2171 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2171's revenue (114.3% per year) is forecast to grow faster than the Hong Kong market (7.8% per year).
High Growth Revenue: 2171's revenue (114.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2171 is forecast to be unprofitable in 3 years.